ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Virios Therapeutics, Inc. (VIRI) stock surged +12.40%, trading at $0.16 on NASDAQ, up from the previous close of $0.14. The stock opened at $0.21, fluctuating between $0.14 and $0.21 in the recent session.
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
Employees | 4 |
Beta | 1.58 |
Sales or Revenue | $0.00 |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |